ArticleFrontiers in public health2025
Public spending on immunisation in Poland.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Vaccination is a proven method for preventing infectious diseases and their complications at individual and community levels. This study aimed to estimate actual public spending on immunisation and compare it with expenditures in other categories of direct medical costs and indirect costs related to absenteeism. Methods: The analysis was based on previously published modelling framework Results: The annual healthcare budget in 2024 in Poland was €44,752 million, of which €6,087 million (13.6%) was allocated to drug and €769 million (1.7%) to prevention. The immunisation programme cost €206 million (0.5%), with vaccine acquisition accounting for 91% of total immunisation costs. The annual per capita cost of vaccines was €4.99, which was notably lower than per capita reimbursement costs for drug classes used to treat diabetes (€12.12), cardiovascular diseases (€12.67), nervous system diseases (€9.42), and respiratory diseases (€7.68). Additionally, the total cost of absenteeism due to vaccine-preventable diseases (€371 million) significantly exceeded the total annual expenditure on the immunisation programme in Poland. Conclusion: With 1.7% of its healthcare budget allocated to prevention and 0.5% to vaccinations, Poland remains a country that invests relatively little in preventive measures. Given the high return on investment in immunisation-through reductions in both direct and indirect costs and in severe outcomes-increased and sustainable public funding for vaccination should be prioritised by healthcare policymakers. Sustainable public investment is crucial to addressing key immunisation challenges: low coverage, delayed introduction of cost-effective vaccines and service quality gaps. Rather than being driven by international expenditure comparisons, this investment should be justified by the evidence-based potential of immunisation to reduce the health and economic burden of vaccine-preventable diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.